Lonidamine as a modulator of taxol activity in human ovarian cancer cells: Effects on cell cycle and induction of apoptosis

International Journal of Cancer

Volumn 78, Issue 3, 1998, Pages 377-384

  Orlandi, Linda ^a   Zaffaroni, Nadia ^a,b   Bearzatto, Alessandra ^a   Villa, Raffaella ^a   De Marco, Cinzia ^a   Silvestrini, Rosella ^a  

^a Pediatric Oncology Unit   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; LONIDAMINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDAZOLES; MITOTIC INDEX; OVARIAN NEOPLASMS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROTAMINE KINASE; TUBULIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032578682     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981029)78:3<377::AID-IJC20>3.0.CO;2-2     Document Type: Article

References (43)

1. BEHRENS, B.C., HAMILTON, T.C., MASUDA, H., GROTZINGER, K.R., WHANGPENG, J., LOUIE, K.G., KNUTZEN, T., MCKOY, W.M., YOUNG, R.C. and OZOLS, R.F., Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47, 414-418 (1987).
2. 13C nuclear magnetic resonance studies. Cancer Res., 55, 2814-2821 (1995).
3. wafl and p53 requires c-raf-1. Cancer Res., 55, 4623-4626 (1995).
4. CHOU, T.C. and TALALAY, P., Quantitative analysis of dose-effect relationship: the combined effect of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55 (1984).
5. CITRO, G., Cucco, C., VERDINA, A. and ZUPI, G., Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Brit. J. Cancer, 64, 534-536 (1991).
6. COLEMAN, T.R. and DUNPHY, W.G., Cdc2 regulatory factors. Curr. Opin. Cell Biol., 6, 877-882 (1994).
7. DANESI, R., FIGG, W.D., REED, E. and MYERS, C.E., Paclitaxel (Taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol. Pharmacol., 47, 1106-1111 (1995).
8. DE LENA, M., LORUSSO, V., BOTTALICO, C., BRANDI, M., DE MITRIO, A., CATINO, A., GUIDA. M., LATORRE, A., LEONE, B., VALLEJO. C. and GARGANO, G., Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J. clin. Oncol., 15, 3208-3213 (1997).
9. DOGLIOTTI, L. and 14 OTHERS, Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. clin. Oncol., 14, 1165-1172 (1996).
10. cdc2 coincident with taxol-induced apoptosis. Cell Growth Differentiation, 5, 1041-1050 (1994).
11. EINZIG, A.I., WIERNIK, PH., SASLOFF, J., RUNOWICZ, C.D. and GOLDBERG, G.L., Phase II study and long-term follow-up of patients treated with paclitaxel for advanced ovarian adenocarcinoma. J. clin. Oncol., 10, 1748-1753 (1992).
12. FERNANDES-ALNEMRI, T., LITWACK, G. and ALNEMRI, E.S., Mch2, a new member of the apoptotic ced-3/ice cysteine protease gene family. Cancer Res., 55, 2737-2742 (1995a).
13. FERNANDES-ALNEMRI, T., TAKAHASHI, A., ARMSTRONG, R., KREBS, J., FRITZ, L., TOMASELLI, K.J., WANG, L., YU, Z., CROCE, C.M., SALVESON, G., EARNSHAW, W.C., LITWACK, G. and ALNEMRI, E.S., Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res., 55, 6045-6052 (1995b).
14. FLORIDI, A., BAGNATO, A., BIANCHI, C., PAGGI, M.G., NISTA, A., SILVESTRINI, B. and CAPUTO, A., Kinetics of inhibition of mitochondrial respiration by the antineoplastic agent lonidamine. J. Exp. clin. Cancer Res., 5, 273-280 (1986).
15. FLORIDI, A., PAGGI, M.G., D'ATRI, S., DE MARTINO, C., MARCANTE, M.L., SILVESTRINI, B. and CAPUTO, A., Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res., 41, 4661-4666 (1981).
16. GIANNAKAKOU, P., VILLALBA, L., LI, H., PORUCHYNSKY, M. and FOJO, T., Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer, 75, 57-63 (1998).
17. HAHN, G.M., VANKERSEN, I. and SILVESTRINI, B., Inhibition of the recovery from potentially lethal damage by lonidamine. Brit. J. Cancer, 50, 657-660 (1984).
18. HALDAR, S., CHINTAPALLI, J. and CROCE, C.M., Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56, 1253-1255 (1996).
19. L overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differentiation, 7, 1984-1094 (1996).
20. KAUFMANN, S.H., DESNOYERS, S., OTTAVIANO, Y., DAVIDSON, N.E. and POIRIER, G.G., Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53, 3976-3985 (1993).
21. KIM, J.H., ALFIERI, A.A., KIM, S.H. and YOUNG, C.W., Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res., 46, 1120-1123 (1986).
22. KROEMER, G., The proto-oncogene bcl-2 and its role in regulating apoptosis. Nature (Med.), 3, 614-620 (1997).
23. LEWIN, B., Driving the cell cycle: M phase kinase, its partners, and substrates. Cell, 61, 743-752 (1990)
24. LING, Y.H., PRIEBE, W. and PEREZ-SOLER, R., Apoptosis induced by anthracycline in P388 parent and multidrug-resistant cells. Cancer Res., 53, 1845-1852 (1993).
25. LIU, X., KIM, C.N., YANG, J., JEMMERSON, R. and WANG, X., Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochromec. Cell 86, 147-157 (1996).
26. LOPES, N.M., ADAMS, E.G., PUTS, T.W. and BHUYAN, B.K., Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol, 32, 235-242 (1993).
27. MANFREDI, J.J. and HORWITZ, S.B., Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther., 25, 83-125 (1984).
28. MILROSS, C.G., PETERS, L.J., HUNTER, N.R., MASON, K.A. and MILAS, L., Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo. Int. J. Cancer, 62, 599-604 (1995).
29. NICHOLSON, D.W. and 15 OTHERS, Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376, 37-43 (1995).
30. NING, S. and HAHN, G.M., Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res. 50, 7867-7870 (1990).
31. ROSBE, K.W., BRANN, T.W., HOLDEN, S.A., TEICHER, B.A. and FREI, E., Effect of lonidamine on the cytotoxicity of four alkylating agents in vivo. Cancer Chemother. Pharmacol., 25, 32-36 (1989).
32. SCHIFF, P.B., FANT, J. and HORWITZ, S.B., Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277, 665-667 (1979).
33. SCHIFF, P.B. and HORWITZ, S.B., Taxol stabilizes microtubules in mouse fibroblast cells. Proc. nat. Acad. Sci. (Wash.), 77, 1561-1565 (1980).
34. SHIOKAWA, D., MARUTA, H. and TANUMA, S. Inhibitors of poly(ADP-ribose) polymerase suppress nuclear fragmentation and apoptotic-body formation during apoptosis in HL-60 cells. FEBS Lett., 413, 99-103 (1997).
35. SILVESTRINI, R., ZAFFARONI, N., VILLA, R., ORLANDI, L. and COSTA, A., Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int. J. Cancer, 52, 813-817 (1992).
36. STEW ART, B.W., Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J. not. Cancer Inst., 17, 286-296 (1994).
37. STROBEL, T., SWANSON, L., KORSMEYER, S. and CANNISTRA, S.A., BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. nat. Acad. Sci. (Wash.), 93, 14094-14099 (1996).
38. TRICHER, B.A., Lonidamine: in vitro/in vivo correlations. Europ. J. Cancer, 30A, 1411-1413 (1994).
39. TISHLER, R.B., SCHIFF, P.B., GEARD, C.R. and HALL, E.J., Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys., 22, 613-617 (1992).
40. VILLA, R., ZAFFARONI, N., BEARZATTO, A., COSTA, A., SICHIROLLO, A. and SILVESTRINI, R., Effect of ionizing radiation on cell-cycle progression and cyclin B1 expression in human melanoma cells. Int. J. Cancer, 66, 104-109 (1996).
41. WOLF, C.M., REYNOLDS, J.E., MORANA, S.J. and EASTMAN, A., The temporal relationship between protein phosphatase ICE/CED-3 proteases, intracellular acidification, and DNA fragmentation in apoptosis. Exp. Cell Res., 230, 22-27 (1997).
42. XIANG, J., CHAO, D.T. and KORSMEYER, S.J., BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc. nat. Acad. Sci. (Wash.), 93, 14559-14563 (1996).
43. ZAFFARONI, N., VILLA, R., ORLANDI, L. and COSTA, A., Combined effects of lonidamine and hyperthermia on malignant melanoma and lung carcinoma surgical specimens. Anticancer Res., 12, 247-250 (1992).